Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC, No. 17-2508 (Fed. Cir. 2019)Annotate this Case
Athena Diagnostics is the exclusive licensee of the 820 patent, covering methods for diagnosing neurological disorders by detecting antibodies to a protein called muscle-specific tyrosine kinase (MuSK), which is associated with Myasthenia gravis (MG), a neurological disorder where patients experience muscle weakness and symptoms including drooping eyelids, double vision, and slurred speech. Athena markets a test (FMUSK) that functions by evaluating those antibodies. After Mayo developed two competing tests, Athena accused Mayo of infringing its patent. The Federal Circuit affirmed that the asserted claims of the 820 patent are invalid under 35 U.S.C. 101, for claiming ineligible subject matter. The claims at issue are directed to a natural law and lack an inventive concept.
The court issued a subsequent related opinion or order on February 14, 2019.
The court issued a subsequent related opinion or order on July 3, 2019.
The court issued a subsequent related opinion or order on July 5, 2019.